Intra-Cellular Therapies, Inc. (ITCI)
NASDAQ: ITCI · Real-Time Price · USD
131.84
+0.03 (0.02%)
Mar 31, 2025, 9:53 AM EDT - Market open
Intra-Cellular Therapies Revenue
In the year 2024, Intra-Cellular Therapies had annual revenue of $680.85M with 46.62% growth. Intra-Cellular Therapies had revenue of $199.22M in the quarter ending December 31, 2024, with 50.81% growth.
Revenue (ttm)
$680.85M
Revenue Growth
+46.62%
P/S Ratio
19.97
Revenue / Employee
$791,688
Employees
860
Market Cap
14.02B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 680.85M | 216.48M | 46.62% |
Dec 31, 2023 | 464.37M | 214.06M | 85.51% |
Dec 31, 2022 | 250.31M | 166.51M | 198.69% |
Dec 31, 2021 | 83.80M | 60.99M | 267.35% |
Dec 31, 2020 | 22.81M | 22.75M | 37,537.14% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
ITCI News
- 4 weeks ago - INTRA-CELLULAR THERAPIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intra-Cellular Therapies, Inc. - ITCI - Business Wire
- 5 weeks ago - Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2024 Financial Results - GlobeNewsWire
- 2 months ago - Healthy Returns: Biotech and pharma M&A is off to a good start in 2025 — but will it last? - CNBC
- 2 months ago - Top 4 Health Care Stocks You May Want To Dump In Q1 - Benzinga
- 2 months ago - SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ENFN and ITCI on Behalf of Shareholders - PRNewsWire
- 2 months ago - Johnson & Johnson to Acquire Intra-Cellular in $15 Billion Deal - WSJ
- 2 months ago - Drugmakers rush to sign deals on first day of industry conference - Reuters
- 2 months ago - Like Bristol-Myers Squibb And AbbVie, Johnson & Johnson Seeks To Bolster Neuropsychiatric Portfolio With $15 Billion Deal - Benzinga